Drugs / rMenB+OMV NZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06995430 | Jul → Dec 2025 | meningitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06995430 ↗ |
| Modality | Vaccine | “meningococcal group B vaccine” NCT06995430 ↗ |